Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile

Author(s): Gianluca Moroncini, Lisa Albani, Lorenzo Nobili, Armando Gabrielli

Journal Name: Current Drug Safety

Volume 11 , Issue 1 , 2016

Become EABM
Become Reviewer
Call for Editor


The discovery of some key molecular mechanisms underlying the dysregulation of the immune system responsible for inflammatory systemic diseases as severe as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), and Systemic Vasculitides, led to the development and subsequent introduction into clinical practice of biological drugs which are significantly improving the management of such complex disorders. This novel molecular targeted therapeutics represents in fact a valid alternative or complementary treatment to conventional immunosuppressive strategies, characterized by broad, unspecific actions and severe adverse effects. Main advantages of the use of biologic drugs reside in their steroid-sparing effect and in the ability of inducing remission of refractory disease states or curing specific organ involvements. Aim of this article is to review and briefly discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the canonical drugs.

Keywords: Belimumab, imatinib, infliximab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), systemic vasculitis, tocilizumab.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 12 February, 2016
Page: [44 - 46]
Pages: 3
DOI: 10.2174/1574886310666151014115251

Article Metrics

PDF: 62
PRC: 1